Methods for the diagnosis and treatment of t cell-lymphomas

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. The Inventors showed that malignant T cells express CD33 in patients with Sézary syndrome, mycosis fungoides and Hepatosplenic T-cell lymphoma (HSTL). CD33 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas.

Keywords: CD33, Diagnostic, Treatment Prediction, T-cell Lymphoma, Sézary Syndrome, Flow-Cytometry
Patent Application number: European Procedure (Patents) (EPA) - 15 Avr. 2022 - 22 305 558.3 and PCT/EP2023/059761 on 14/04/2023
Inventors:
BENSUSSAN ArmandBAGOT MartineDE MASSON AdeleGIUSTINIANI Jérôme

Reference:

BIO22146-D1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 15-04-2022
Rare disease: No
Second indication: No

You might also be interested in